Companies › Sangamo Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ST-503 Gene therapy delivering modified gene to repress Nav1.7 (SCN9A) tissue-related pain signal | Ion channels | Phase 1 | Chronic Neuropathic Pain | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06980948 | ST-503 | Phase 1 | Chronic Neuropathic Pain | Neurology | Jul 2027 |
Cash of $28m on 2026-03-31; operating cash outflow about $79m a year; runway about 4 months at that burn, to Aug 2026
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.